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Abstract  
BACKGROUND: Liver fibrosis is the common pathologic consequence of all chronic liver diseases.  
AIM: Lactoferrin (Lf) was investigated for its possible hepatoprotective effect against thioacetamide 
(TAA)-induced liver fibrosis rat model.  
MATERIAL AND METHODS: Rats received TAA (200 mg/kg/biweekly, ip) for four successive 
weeks. Lf (200 mg/kg/day, p.o.) or vehicle (VHC) was administered for one month before and 
another month during TAA injection. Body weight and mortality rate were assessed during the 
month of TAA-intoxication. Thereafter, serum and liver tissues were analyzed for liver function, 
oxidative, fibrotic and apoptotic markers.  
RESULTS: Lf conserved rats against TAA-induced body weight-loss and mortality. Preservation of 
serum albumin, alkaline phosphatase and total bilirubin levels was also observed. Lf also protected 
rats against TAA-induced decrease in reduced glutathione and increase in malondialdehyde liver 
contents. Normal liver contents of hydroxyproline, nuclear factor kappa B and alpha fetoprotein; as 
markers of fibrosis; were increased with TAA and conserved with Lf-TAA. Lf maintained the normal 
architecture of the liver and immunohistochemical findings revealed increase in apoptotic bodies 
compared to TAA that favored necrosis.  
CONCLUSION: In conclusion, Lf improved liver function, reduced oxidative stress and liver fibrosis, 
and enhanced apoptosis in rats with liver fibrosis, suggesting it to have useful therapeutic potential 
in patients with liver fibrosis.    
 
 
 
 
 
Introduction 
 
Liver fibrosis is a major global health problem 
causing approximately 1.4 million deaths per year [1]. 
It is the common pathologic consequence of all 
chronic liver diseases. Its  principal causative factors 
in developing countries are viral infection with 
hepatitis B and C and parasitic infection with 
Schistosoma Mansoni, while it is excessive alcohol 
consumption in developed countries [2]. Some drugs, 
autoimmune diseases and genetic disorders are also 
contributed to liver fibrosis [3-5]. Persistent 
inflammation caused by chronic liver injury, resulted in 
aberrant wound healing response with excessive 
deposition of extracellular matrix (ECM) in the space 
of Disse that leads to disruption of normal 
microanatomy of liver sinusoids [6]. The principal 
cellular source of ECM has been reported to hepatic 
stellate cells (HSCs) [7], which activated from a 
quiescent, vitamin A storing cell to an activated 
myofibroblast-like phenotype under influence of 
inflammatory mediators and growth factors [8]. Once 
activated, HSCs up-regulate gene expression 
responsible for synthesis of ECM components, 
leading to deposition of collagen I and III, elastin and 
glycoproteins in the space of Disse [9]. Activated 
HSCs themselves secrete inflammatory mediators, a 
vicious cycle is formed, and a perpetual process of 
liver damage and repair leads to continuous 
deposition of ECM [10]. 
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Liver fibrosis could be considered a 
bidirectional process and could be reversible [11]. The 
hope is that if antifibrotic therapy can reconstitute the 
normal balance of liver, normal function can be 
restored and clinical manifestations may regress. 
Current and evolving approaches primarily target to 
inhibit the activated HSCs, proliferation, and products 
as well as enhance their apoptosis [12].  
Lactoferrin (Lf) is a natural glycoprotein found 
predominantly in milk [13]. It has multi-
pharmacological properties that are mediated through 
specific receptors present on the surface of many 
cells [14, 15]. Lf is well known for its anti-bacterial, 
anti-fungal and anti-parasitic activities [15, 16]. It also 
has anti-viral effect against wide range of viruses 
including hepatitis C (HCV), human 
immunodeficiency, herpes simplex and 
cytomegalovirus [14, 17], and showed anti-
carcinogenic effect against many tumor cells [18, 20].  
In liver, Lf prevented hepatocellular necrosis 
and revealed a direct cytoprotective function through 
anti-oxidant activity [21]. Lf has been also found to 
inhibit HSCs activation through a potent anti-
inflammatory effect [22]. In contrast, it favored HSCs 
apoptosis through induction of natural killer cells (NK), 
macrophages and CD8+ T-lymphocytes [23]. The role 
of Lf against liver fibrosis has not been elucidated yet. 
Nevertheless, a potential anti-fibrotic action may be 
returned to its anti-inflammatory, anti-oxidant and pro-
apoptotic actions. The current study was conducted to 
evaluate this possible antifibrotic effect of Lf against 
liver fibrosis induced experimentally in rats using 
thioacetamide (TAA); a model that results in 
biochemical and histological changes similar to that of 
human liver fibrosis [24].  
 
 
Materials and Methods 
 
Animals 
Adult male albino Wistar rats, weighing 200-
250 g, were obtained from animal house colony of 
National Research Center (NRC) (Giza, Egypt), and 
treated according to ethics guidelines stated by the 
ethics committee of NRC.  
 
Drugs and chemicals 
TAA was obtained from Loba Chemie (India) 
as creamy white crystals freely soluble in water, and 
freshly prepared as solution in saline (0.9% NaCl) for 
intraperitoneal (ip) injection in rats. 
Lf was obtained from Radiance Nutritional 
Company (New Zealand) as pinkish white crystals 
slightly soluble in water, and freshly prepared as 
suspension in 1% (v/v) Tween 80 in distilled water for 
oral administration. 
 
Experimental Design 
Thirty six rats were randomly allocated into 
three groups; the 1
st
 received vehicles (VHC) and 
served as normal (VHC group), while the 2
nd
 and 3
rd
 
groups served as liver fibrosis-model group (TAA 
group) and Lf-treated group (Lf-TAA group), 
respectively. VHC group received saline ip twice 
weekly for four weeks. In the other two groups, liver 
fibrosis was induced using TAA (200 mg/kg/biweekly, 
ip) [25], on Sundays and Wednesdays, for four 
successive weeks. For one month before and another 
month during induction of liver fibrosis, rats of VHC (n 
= 6) and TAA (n = 18) groups received daily oral dose 
of 1% (v/v) tween 80 in distilled water, while rats of Lf-
TAA group (n = 12) received Lf (200 mg/kg/day, p.o.) 
[26]. 
 
Assessment of body weight change and 
mortality percent 
Body weights of rats in each group were 
measured weekly during the month of liver fibrosis 
induction to monitor their growth rate. The number of 
rats in each group at the beginning and end of the 
experiment was also recorded, and mortality percent 
was determined. 
 
Serum biochemical analysis 
Twenty four hours following the last TAA 
injection, blood samples were withdrawn from six rats 
per group via retro-orbital vein under light ether 
anesthesia [27]. Serum was used for estimation of 
albumin, alkaline phosphatase (ALP) and bilirubin 
levels, using specific diagnostic kits (Biodiagnostic, 
Egypt). 
 
Tissue biochemical analysis 
Immediately after blood sampling, animals 
were sacrificed by cervical dislocation under ether 
anesthesia, livers were rapidly removed, washed in 
ice-cooled saline and plotted dry. A weighed part of 
each liver was homogenized, and the homogenate 
was used for assessment of; reduced glutathione 
(GSH) and lipid peroxides measured as 
malondialdehyde (MDA) contents using 
(Biodiagnostic, Egypt) kits, nuclear factor kappa B 
(NF-ҡB) and alpha-fetoprotein (AFP) contents using 
specific diagnostic kits (Glory Science, USA), as well 
as hydroxyproline (HP) content according to 
Woessner assay [28]. 
Histopathological and Immunohistochemical 
examination 
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Specimens from three major lobes of the liver 
tissue were dissected immediately after scarification, 
formalin-fixed and paraffin-embedded according to 
Carleton (1980) [29]. For histopathological 
investigation, serial sections of 6 μm thick were cut 
and stained with Haematoxylin and Eosin (H&E), 
Masson Trichrome (MT) stains. Additionally, apoptotic 
cells in liver tissue sections were determined 
immunohistochemically by Terminal deoxy Uridine 
triphosphate Nick End Labeling (TUNEL) assay [30]. 
Apoptotic cells were identified by a brown stain over 
the nuclei. All sections were scanned and analyzed, 
and images were captured and processed using 
Adobe Photoshop version 8.0. 
 
Statistical analysis 
Results were expressed as mean ± standard 
error (SE) of the mean. Data were statistically 
analyzed using Stat-graphics Centurion ΧV version 
15.2.06, Stat point, Inc. Data of rat body weights were 
analyzed using repeated measures two-way analysis 
of variance (ANOVA) to test for interaction between 
drug type, time and body weight followed by least 
significant difference (LSD) multiple range test. All 
other data were statistically analyzed using One-way 
ANOVA followed by LSD multiple range test. For all 
data, a probability of less than 0.05 was used as 
criterion for statistical significance.  
 
Results 
Body weight and mortality percent 
Body weights of VHC-treated rats were 
increased by 26% throughout the month of TAA-
induced liver fibrosis, while they were decreased by 
18% in TAA group. In Lf-TAA-treated animals, body 
weights were increased up to 108% (Fig. 1). No 
mortality was observed in VHC group, while it reached 
67% and 25% in TAA and Lf-TAA groups, 
respectively.  
 
Figure 1: Rats body weight. VHC, rats treated with vehicles; TAA, rats treated with 
thioacetamide; Lf-TAA, rats treated with lactoferrin and thioacetamide. 
a
Significantly 
different from VHC at respective time; P ˂ 0.05. 
b
Significantly different from TAA at 
respective time; P ˂ 0.05. 
Serum parameters 
TAA-induced liver fibrosis rat model markedly 
decreased normal serum albumin and increased 
serum ALP and bilirubin levels. In Lf-TAA-treated rats, 
normal serum albumin and ALP levels were 
preserved.  Though, Lf failed to alter TAA-induced 
increase of serum bilirubin level (Table 1).  
Table 1: Serum albumin, alkaline phosphatase and bilirubin 
levels. 
 Parameters 
Groups 
Albumin (g/dl) ALP (IU/l) Bilirubin (mg/dl) 
VHC 3.82
b 
± 0.24 109.25
b 
± 3.96 0.70
b 
± 0.07 
TAA  3.09
a 
± 0.16 116.03
a 
± 0.52 1.01
a 
± 0.02 
Lf-TAA 3.70
b 
± 0.28 113.16 ± 0.22 1.07
a 
± 0.04 
VEH, rats treated with vehicles; TAA, rats treated with thioacetamide; Lf-TAA, rats treated 
with lactoferrin and thioacetamide; ALP, Alkaline phosphatase. Data are presented as 
mean ± SE, n=6. 
a
Significantly different from VHC; P˂ 0.05. 
b
Significantly different from 
TAA; P˂ 0.05.  
 
Tissue parameters 
Normal liver MDA content was increased in 
TAA-liver fibrosis rat model to 141% and GSH was 
decreased to 30%. Furthermore, TAA increased 
normal liver contents of HP, NF-ҡB and AFP to 201%, 
198% and 153%, respectively. In Lf-TAA group, 
normal liver contents of all measured tissue 
parameters were conserved (Table 2). 
 
Histopathological and immunohistochemical 
features (Fig. 2, 3, and 4)  
Compared to VHC group, liver sections of 
TAA-treated rats revealed disorganized lobular pattern 
with hepatic fibrosis and extensive fibroblastic 
proliferation. Portal area revealed marked dilatation 
and   congestion   of   portal   vessels,  portal  fibrosis,  
 
Table 2: Liver contents of malondialdehyde, reduced 
glutathione, hydroxyloroline, nuclear factor kappa B and alpha 
fetoprotein. 
Parameters 
Groups 
MDA (mmol/g) GSH (mmol/g) HP (µg/g) NF-ҡB (ng/g) AFP (ng/g) 
VHC 149.36b ± 10.48 8.13b ± 0.43 25.52b ± 1.09 7.01b ± 0.54 8.21b ± 0.43 
TAA  210.20a ± 11.13 2.43a ± 0.20 51.59a ± 3.78 13.88a ± 1.19 12.55a ± 0.63 
Lf-TAA 149.59b ± 13.71 8.29b ± 0.43 30.91b ± 1.85 8.56b ± 0.65 8.56b ± 0.68 
VEH, rats treated with vehicles; TAA, rats treated with thioacetamide; Lf-TAA, rats treated 
with lactoferrin and thioacetamide; MDA, Malondialdehyde; GSH, Reduced glutathione; 
HP, Hydroxyproline; NF-κ B, Nuclear factor kappa B; AFP, Alpha fetoprotein. Data are 
presented as mean ± SE, n = 6. 
a
Significantly different from VHC; P ˂  0.05. 
b
Significantly 
different from TAA; P ˂  0.05. 
 
 
hyperplasia of biliary epithelium and formation of 
newly formed bile ductules. Intense fibroblastic 
proliferation, extended to infiltrate the surrounding 
hepatic parenchyma, mixed with oval cells and biliary 
cyst formation, were also demonstrated.  
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Figure 2: Photomicrograph of rats hepatic lobules. Liver sections from rats treated with 
VHC (A, D), TAA (B, E) and Lf-TAA (C, F), stained with H&E stain (A, B, C) and MT stain 
(D, E, F). Histopatological examination showed (A) normal hepatic architecture and 
preserved lobular pattern, (b) hepatic fibrosis and extensive fibroblastic proliferation 
(arrow), (C) preserved lobular pattern, (D) no evidence of fibrosis or inflammatory reaction 
in hepatic lobules, (E) blue-stained fibrous connective tissue (arrow) and (F) very delicate 
blue-stained fibrous tissue (arrow) encircling hepatic lobules. 
Hepatocytes showed hypertrophy with large 
karyomegallic nuclei and prominent nucleoli 
associated with focal area of necrosis infiltrated with 
mononuclear cells with presence of few apoptotic 
cells. Immunohistochemical demonstration of cleaved 
caspase-3-positive hepatocytes in which putative pre-
apoptotic hepatocytes could be identified, was 
characterized by a positive antibody-reaction with 
cytoplasmic and nuclear localization. 
 
Figure 3: photomicrograph of rats portal triad.  Liver sections from rats treated with VHC 
(A, E), TAA (B, C, F) and Lf-TAA (D, G), stained with H&E stain (A, B, C, D) and MT stain 
(E, F, G). Histopatological examination showed (A) normal portal area, (B) dilatation and 
congestion of portal blood vessels, portal fibrosis, hyperplasia of biliary epithelium and 
formation of newly formed bile ductules (arrow), (C) intense fibroblastic proliferation 
(arrow) mixed with oval cells and biliary cyst formation, (D) normal portal area with few 
mononuclear cell infiltration associated with vacuolar degeneration of the surrounding 
hepatocytes (arrow), (E) normal portal area (arrow),  (F) blue stained fibrous connective 
tissue expanding portal area (arrow) and (G) portal area less expanded by blue stained 
fibrous connective tissue (arrow). 
In Lf-TAA group, less inflammatory changes 
were observed with preserved lobular pattern and 
very delicate deposition of fibrous tissue in hepatic 
lobules  and  portal  area.  Portal  infiltration  with  few 
mononuclear cells associated with vacuolar 
degeneration of the surrounding hepatocytes, was 
also observed. Hepatocytes were greatly similar to 
those of VHC group; however, presence of apoptotic 
cells was demonstrated. Immunohistochemical-
stained cleaved caspase-3-positive hepatocytes 
showed more positive antibody-reacting hepatocytes 
compared to TAA group. 
 
Figure 4: Histopathological and immunohistochemical analysis of apoptosis. Liver sections 
from rats treated with VHC (A, D), TAA (B, E) and Lf-TAA (C, F), stained with H&E stain 
for histopathological examination (A, B, C) and immunohistochemically analysed for 
cleaved caspase-3-positive hepatocytes (D, E, F),  showed (A) no evidence of necrosis or 
apoptosis, (B) focal area of hepatocellular necrosis infiltrated with mononuclear cells with 
presence of apoptotic cells (arrow), (C) apoptotic cells (arrow), (D) cleaved caspase-3-
negative hepatocytes, (E) pre-apoptotic hepatocytes characterized by a positive antibody-
reaction with cytoplasmic (long arrow) and nuclear localization (short arrow) and (F) 
cleaved caspase-3-positive hepatocytes with cytoplasmic (long arrow) and  nuclear (short 
arrow) staining. 
 
 
Discussion 
Induction of liver fibrosis through TAA caused 
marked toxicity in rats revealed by their inability to 
gain body weight. Previous studies attributed the 
same outcome to lower levels of nutrient absorption 
and metabolic efficiency after exposure to TAA [31, 
32]. In Lf-TAA group, weight gain was nearly parallel 
to those in normal group. This suggests that Lf 
diminished the negative effect of TAA on growth rate 
[26]. 
Mortality rate observed in TAA group is 
corresponding with many previous studies reported 
elevated mortality rate within rats with TAA-induced 
liver fibrosis [32, 33]. In Lf-TAA rats, mortality rate was 
reduced in agreement with another study found Lf to 
reduce mortality rate in mice with acetaminophen-
induced liver injury [21]. 
Albumin is a plasma protein that is 
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synthesized solely in liver and its serum level 
correlates with hepatocellular synthesis capacity [34]. 
The current hypoalbunimea in TAA-treated rats 
reflects liver impaired ability. Previous studies [35, 36] 
contributed the same finding to extensive hepatocytes 
damage and alterations in their synthetic mechanisms 
by TAA-hepatotoxic metabolites [36]. Lf significantly 
prevented this hypoalbunimea which reflects the 
maintenance of normal hepatocellular synthesis 
capacity. Similarly, other studies showed that Lf 
stimulates kupffer cells to produce cytoprotective 
mediators [21] and it can retain the normal ability of 
hepatocytes to synthesize albumin [37].  
Correspondingly, the current elevated serum 
activity of ALP in TAA group is accounted to hepatic 
parenchymal damage with subsequent diminished 
liver function capacity that lead to elevated serum 
activity of liver enzymes than normal; including ALP 
[38], a result consistent with the work of Galisteo et al 
[39]. Lf in the current experiment maintained normal 
serum ALP activity. These results are consistent with 
results of previous studies [40, 41]. 
Serum bilirubin had been markedly elevated 
in TAA-treated rats, a result in agreement with 
previous studies [2, 42]. Physiologically, bilirubin is a 
haem product that undergoes catalysis and 
conjugation with glucuronic acid in hepatocytes before 
being excreted into bile. Hyperbilirubinemia indicates 
liver failure to conjugate and excrete bilirubin [2]. Lf 
failed to maintain normal bilirubin serum level in this 
study, a result against that of earlier study [26] in 
which Lf restored normal bilirubin level in rat model of 
colitis. The proposed explanation of this controversy is 
that the earlier study used Lf for double the duration 
used in the current study and according to Al-Jumaily 
and Khaleel [43]; prolonged time is needed to restore 
normal serum bilirubin level.  
Marked oxidative stress was observed in 
current TAA liver fibrosis rat model, evidenced by rise 
in liver content of lipid peroxidation end product, MDA, 
and decline in GSH content. Obtained results are in 
agreement with other studies [44, 45] and attributed to 
TAA biotransformation with extensive production of 
reactive oxygen species (ROS) exceeding the 
capacity of endogenous antioxidant protective 
mechanisms; including GSH, to eliminate them, and in 
turn, GSH depletion [46]. Under influence of these 
ROS, MDA are produced from oxidation of 
polyunsaturated fatty acids in biomembranes [47]. Lf 
markedly prevented this TAA-induced oxidative 
stress, prevented MDA accumulation and GSH 
depletion. Consistently, other studies showed 
antioxidant effect of Lf [48-50]. 
HP is a major component of collagen that 
formulates the highest share of ECM deposits, and so, 
considered as a sensitive marker of fibrosis [25]. In 
the present TAA group, liver HP content was 
increased. Similarly, several studies reported 
significant elevation in HP and collagen contents in 
rats subjected to TAA intoxication [25, 36, 44]. 
Additionally, several studies strongly implicated NF-ĸB 
as a potential master orchestrator in liver fibrosis [51, 
52]. After activation with pro-inflammatory cytokines; 
NF-ĸB becomes the driving force of fibrosis. It 
activates the major fibrogenic molecule; tissue growth 
factor beta (TGF-β), and stimulates the survival and 
production of activated myofibroblasts through 
differentiation of HSCs [53]. NF-ĸB-liver content was 
increased in the present TAA liver fibrosis model in 
correspondence with another study [54].  In Lf-TAA-
treated rats, normal tissue contents of both HP and 
NF-κB were preserved, a result in harmony with that 
of Togawa et al [26] and other studies postulated that 
attenuation of NF-κB plays an important role in 
fundamental block of developing fibrosis and 
subsequently, decreases tissue HP content [48, 55]. 
AFP is often measured as a tumor marker for 
diagnosing hepatocellular carcinoma (HCC). 
However, recent studies postulated that AFP can be 
used in diagnosis and assessment of liver fibrosis 
without the presence of HCC [10, 56]. Currently, a 
Marked increase in liver content of AFP was observed 
in TAA group in consistence with another study [57], 
while, its normal liver content was maintained in Lf-
TAA group. This result reflects the hepatoprotective 
ability of Lf against liver fibrosis induced by TAA and 
supported by the work of Harn et al [10] showed 
maintenance of AFP content in liver to be an indicator 
of protection against fibrosis.  
The current histopathological and immuno-
histochemical manifestations seem to be in 
accordance with the present biochemical findings. 
Liver fibrosis revealed in TAA group is parallel with the 
findings of previous studies [2, 58], and preservation 
of normal liver architecture with limited collagen 
deposition in Lf-TAA group is consistent with other 
studies [21, 59]. The low rate of apoptosis reported 
immunohistochemically in TAA group is in accordance 
with former study found that TAA injection caused 
mainly necrosis along with minimal apoptosis [31]. 
The high rate of apoptosis detected in Lf-TAA group is 
supported by the results of previous [23] in which Lf 
inhibited growth factors, arrested cell growth and 
stimulated kupffer and NK cells to exert their apoptotic 
actions. This suggests pro-apoptotic actions of Lf 
favored activated-myofibroblasts apoptosis and in turn 
resolution of liver fibrosis. 
Based on all the findings, it could be 
concluded that treatment of rats with Lf (200 
mg/kg/day, po), for one month before and another 
month during TAA intoxication, exhibited marked 
hepatoprotective effect evidenced by biochemical 
results and proven by histopathological and 
immunohistochemical examinations. These findings 
revealed that this hepatoprotective potential is 
possibly through its antioxidant and pro-apoptotic 
actions, as well as, through its inhibitory effect on NF-
κB.  
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This study strongly suggests Lf as a 
promising drug for protection against structural and 
functional changes associated with liver fibrosis. 
Additionally, because Lf has been found to show an 
antiviral activity against HCV [14, 60, 61]; one of the 
most important causative factors of liver fibrosis, the 
current findings suggest additional value of using Lf as 
a hepatoprotective therapy in HCV patients. 
Moreover, many recent studies revealed that Lf could 
be used as a targeting system to deliver drugs to liver 
as it can bind to multiple receptors on hepatocytes 
[62]. The findings of the present study add an 
advantage to the use of such delivery system in 
patients with, or susceptible to, liver fibrosis. 
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